Silas Inman


Lenvatinib/pembrolizumab efficacy in renal cell carcinoma sustained with longer follow-up

September 11, 2022

“These data clearly show that the efficacy benefit observed at the primary analysis was robust and maintained with longer follow-up, once again supporting lenvatinib and pembrolizumab as a standard of care in first-line advanced RCC,” said Camillo G. Porta, MD.